5 Key Takeaways
-
1
Migaldendranib significantly reduced the need for intravitreal injections in patients with DME and nAMD during a phase 2 trial.
-
2
The trial showed a reduction in annualized injection rates from 8.4 to 1.6 in study eyes and from 8.3 to 0.9 in fellow eyes.
-
3
Participants experienced an average gain of 6.1 ETDRS letters in visual acuity for DME eyes, with similar improvements in nAMD.
-
4
No serious adverse events related to the treatment were reported, indicating a favorable safety profile for migaldendranib.
-
5
Monthly, at-home subcutaneous administration of migaldendranib may offer a less burdensome alternative to frequent intravitreal injections.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.